Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation

Journal of Molecular and Cellular Cardiology

Volumn 115, Issue , 2018, Pages 32-38

  Buonafine, Mathieu ^a   Martínez Martínez, Ernesto ^a   Amador, Cristian ^b   Gravez, Basile ^a   Ibarrola, Jaime ^c   Fernández Celis, Amaya ^c   El Moghrabi, Soumaya ^a   Rossignol, Patrick ^a   López Andrés, Natalia ^c   Jaisser, Frédéric ^a  

^a INSERM   (France)

^b UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^c PUBLIC UNIVERSITY OF NAVARRE   (Spain)

Author keywords

Aldosterone; Cardiovascular; Fibrosis; Inflammation; MR; NGAL

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CARDITIS; CD8+ T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; DENDRITIC CELL; FIBROBLAST; FLOW CYTOMETRY; GRANULOCYTE; HEART INJURY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; IMMUNOCOMPETENT CELL; IN VIVO STUDY; KIDNEY INJURY; LYMPH NODE; MACROPHAGE; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CELL CULTURE; CELL PROLIFERATION; FIBROSIS; HEART ATRIUM REMODELING; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; LEUKOCYTE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

ALDOSTERONE; ANIMALS; ATRIAL REMODELING; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; FIBROSIS; HUMANS; INFLAMMATION; LEUKOCYTES; LIPOCALIN-2; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NEPHRECTOMY; OXIDATIVE STRESS;

EID: 85040021182     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2017.12.011     Document Type: Article

References (50)

1. Rogerson, F.M., Fuller, P.J., Mineralocorticoid action. Steroids 65 (2000), 61–73.
2. Briet, M., Schiffrin, E.L., Aldosterone: effects on the kidney and cardiovascular system. Nat. Rev. Nephrol. 6 (2010), 261–273, 10.1038/nrneph.2010.30.
3. Cachofeiro, V., Miana, M., de las Heras, N. et al., Aldosterone and the vascular system. J. Steroid Biochem. Mol. Biol. 109 (2008), 331–335, 10.1016/j.jsbmb.2008.03.005.
4. Latouche, C., El Moghrabi, S., Messaoudi, S. et al., Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension 59 (2012), 966–972, 10.1161/HYPERTENSIONAHA.111.187872.
5. Schmidt-Ott, K.M., Mori, K., Li, J.Y. et al., Dual action of neutrophil Gelatinase-Associated Lipocalin. J. Am. Soc. Nephrol. 18 (2007), 407–413, 10.1681/ASN.2006080882.
6. Liu, F., Yang, H., Chen, H. et al., High expression of neutrophil gelatinase-associated lipocalin (NGAL) in the kidney proximal tubules of diabetic rats. Adv. Med. Sci. 60 (2015), 133–138, 10.1016/j.advms.2015.01.001.
7. Hamzic, N., Blomqvist, A., Nilsberth, C., Immune-induced expression of Lipocalin-2 in brain endothelial cells: relationship with Interleukin-6, Cyclooxygenase-2 and the febrile response. J. Neuroendocrinol. 25 (2013), 271–280, 10.1111/jne.12000.
8. Eilenberg, W., Stojkovic, S., Piechota-Polanczyk, A. et al., Neutrophil gelatinase-associated Lipocalin (NGAL) is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro. Eur. J. Vasc. Endovasc. Surg. 51 (2016), 623–631, 10.1016/j.ejvs.2016.01.009.
9. Kjeldsen, L., Johnsen, A.H., Sengelov, H., Borregaard, N., Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 268 (1993), 10425–10432.
10. Flo, T.H., Smith, K.D., Sato, S. et al., Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 432 (2004), 917–921, 10.1038/nature03104.
11. Floderer, M., Prchal-Murphy, M., Vizzardelli, C., Dendritic cell-secreted Lipocalin2 induces CD8 + T-cell apoptosis, contributes to T-cell priming and leads to a TH1 phenotype. PLoS One, 9, 2014, e101881, 10.1371/journal.pone.0101881.
12. Devarajan, P., Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark. Med 4 (2010), 265–280, 10.2217/bmm.10.12.
13. van Deursen, V.M., Damman, K., Voors, A.A. et al., Prognostic value of plasma neutrophil gelatinase–associated lipocalin for mortality in patients with heart failure. Circ. Heart Fail. 7 (2014), 35–42.
14. Wu, G., Li, H., Fang, Q. et al., Elevated circulating lipocalin-2 levels independently predict incident cardiovascular events in men in a population-based cohort. Arterioscler. Thromb. Vasc. Biol. 34 (2014), 2457–2464 ATVBAHA-114.
15. Tarjus, A., Martínez-Martínez, E., Amador, C. et al., Neutrophil Gelatinase–Associated Lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. Hypertension 66 (2015), 158–166.
16. Montecucco, F., Liberale, L., Bonaventura, A. et al., The role of inflammation in cardiovascular outcome. Curr Atheroscler Rep, 19, 2017, 10.1007/s11883-017-0646-1.
17. Mortensen, R.M., Immune cell modulation of cardiac remodeling. Circulation 125 (2012), 1597–1600, 10.1161/CIRCULATIONAHA.112.097832.
18. Bene, N.C., Alcaide, P., Wortis, H.H., Jaffe, I.Z., Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease. Steroids 91 (2014), 38–45, 10.1016/j.steroids.2014.04.005.
19. Han, M., Li, Y., Liu, M. et al., Renal neutrophil gelatinase associated lipocalin expression in lipopolysaccharide-induced acute kidney injury in the rat. BMC Nephrol., 13(25), 2012.
20. Ip, J.P., Noçon, A.L., Hofer, M.J. et al., Lipocalin 2 in the central nervous system host response to systemic lipopolysaccharide administration. J. Neuroinflammation, 8(1), 2011.
21. Shashidharamurthy, R., Machiah, D., Aitken, J.D. et al., Differential role of lipocalin 2 during immune complex-mediated acute and chronic inflammation in mice: lipocalin 2 during immune complex-mediated inflammation. Arthritis Rheum. 65 (2013), 1064–1073, 10.1002/art.37840.
22. Rubinstein, T., Pitashny, M., Putterman, C., The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/Lipocalin-2 as a biomarker for lupus nephritis. Autoimmun. Rev. 7 (2008), 229–234, 10.1016/j.autrev.2007.11.013.
23. Chakraborty, S., Kaur, S., Guha, S., Batra, S.K., The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys Acta BBA – Rev. Cancer 1826 (2012), 129–169, 10.1016/j.bbcan.2012.03.008.
24. Viau, A., El Karoui, K., Laouari, D. et al., Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J. Clin. Invest. 120 (2010), 4065–4076, 10.1172/JCI42004.
25. El Karoui, K., Viau, A., Dellis, O. et al., Endoplasmic reticulum stress drives proteinuria-induced kidney lesions via Lipocalin 2. Nat. Commun., 7, 2016, 10330, 10.1038/ncomms10330.
26. Helanova, K., Spinar, J., Parenica, J., Diagnostic and prognostic utility of neutrophil gelatinase-associated Lipocalin (NGAL) in patients with cardiovascular diseases - review. Kidney Blood Press. Res. 39 (2014), 623–629, 10.1159/000368474.
27. Choi, K.M., Lee, J.S., Kim, E.J. et al., Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur. J. Endocrinol. 158 (2008), 203–207, 10.1530/EJE-07-0633.
28. Daniels, L.B., Barrett-Connor, E., Clopton, P. et al., Plasma neutrophil gelatinase–associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults. J. Am. Coll. Cardiol. 59 (2012), 1101–1109, 10.1016/j.jacc.2011.11.046.
29. Zografos, T., Haliassos, A., Korovesis, S. et al., Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am. J. Cardiol. 104 (2009), 917–920, 10.1016/j.amjcard.2009.05.023.
30. Yndestad, A., Landrø L., Ueland, T. et al., Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur. Heart J. 30 (2009), 1229–1236, 10.1093/eurheartj/ehp088.
31. Yang B, Fan P, Xu A, et al (2012) Improved functional recovery to I/R injury in hearts from lipocalin-2 deficiency mice: restoration of mitochondrial function and phospholipids remodeling. Am. J. Transl. Res.
32. Tarín, C., Fernandez-Garcia, C.E., Burillo, E. et al., Lipocalin-2 deficiency or blockade protects against aortic abdominal aneurysm development in mice. Cardiovasc. Res. 111 (2016), 262–273, 10.1093/cvr/cvw112.
33. Anne-Louise Hemdahl, A.G., Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 26 (2006), 136–142, 10.1161/01.ATV.0000193567.88685.f4.
34. Sung, H.K., Chan, Y.K., Han, M. et al., Lipocalin-2 (NGAL) attenuates Autophagy to exacerbate cardiac apoptosis induced by myocardial ischemia: LIPOCALIN-2, AUTOPHAGY AND CELL DEATH. J. Cell. Physiol., 2017, 10.1002/jcp.25672.
35. Cheng, L., Xing, H., Mao, X. et al., Lipocalin-2 promotes M1 macrophages polarization in a mouse cardiac ischaemia–reperfusion injury model. Scand. J. Immunol. 81 (2015), 31–38, 10.1111/sji.12245.
36. Harrison, D.G., Guzik, T.J., Lob, H.E. et al., Inflammation, immunity, and hypertension. Hypertension 57 (2011), 132–140, 10.1161/HYPERTENSIONAHA.110.163576.
37. Schiffrin, E.L., The immune system: role in hypertension. Can. J. Cardiol. 29 (2013), 543–548, 10.1016/j.cjca.2012.06.009.
38. Rickard, A.J., Morgan, J., Tesch, G. et al., Deletion of mineralocorticoid receptors from macrophages protects against Deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54 (2009), 537–543, 10.1161/HYPERTENSIONAHA.109.131110.
39. Sun, X.N., Li, C., Liu, Y. et al., T cell mineralocorticoid receptor controls blood pressure by regulating interferon gamma. Circ. Res. 120 (2017), 1584–1597 CIRCRESAHA.116.310480 https://doi.org/10.1161/CIRCRESAHA.116.310480.
40. Amador, C.A., Barrientos, V., Peña, J. et al., Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertens Dallas Tex. 1979 63 (2014), 797–803, 10.1161/HYPERTENSIONAHA.113.02883.
41. Marzolla, V., Armani, A., Feraco, A. et al., Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome. Steroids, 2014, 10.1016/j.steroids.2014.05.001.
42. Aigner, F., Maier, H.T., Schwelberger, H.G. et al., Lipocalin-2 regulates the inflammatory response during ischemia and reperfusion of the transplanted heart. Am. J. Transplant. 7 (2007), 779–788, 10.1111/j.1600-6143.2006.01723.x.
43. Sickinger, S., Maier, H., König, S. et al., Lipocalin-2 as mediator of chemokine expression and granulocyte infiltration during ischemia and reperfusion. Transpl. Int. 26 (2013), 761–769, 10.1111/tri.12116.
44. Schroll, A., Eller, K., Feistritzer, C. et al., Lipocalin-2 ameliorates granulocyte functionality: innate immunity. Eur. J. Immunol. 42 (2012), 3346–3357, 10.1002/eji.201142351.
45. Gilet, A., Zou, F., Boumenir, M. et al., Aldosterone up-regulates MMP-9 and MMP-9/NGAL expression in human neutrophils through p38, ERK1/2 and PI3K pathways. Exp. Cell Res. 331 (2015), 152–163, 10.1016/j.yexcr.2014.11.004.
46. van der Heiden, K., Cuhlmann, S., Luong, L.A. et al., Role of nuclear factor κB in cardiovascular health and disease. Clin. Sci. 118 (2010), 593–605, 10.1042/CS20090557.
47. Martínez-Martínez, E., Buonafine, M., Boukhalfa, I. et al., Aldosterone target NGAL (Neutrophil Gelatinase–Associated Lipocalin) is involved in cardiac remodeling after myocardial infarction through NFκB pathway. Hypertension 70 (2017), 1148–1156 HYPERTENSIONAHA–117.
48. Mori, K., Lee, H.T., Rapoport, D. et al., Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. 115 (2005), 610–621, 10.1172/JCI200523056.
49. Mishra, J., Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated Lipocalin. J. Am. Soc. Nephrol. 15 (2004), 3073–3082, 10.1097/01.ASN.0000145013.44578.45.
50. Fan, D., Takawale, A., Lee, J., Kassiri, Z., Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair, 5, 2012, 15.